First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients
Annals of oncology, 2011-03, Vol.22 (3), p.595-602 [Peer Reviewed Journal]2010 European Society for Medical Oncology ;2015 INIST-CNRS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdq430
Full text available